Literature DB >> 304675

The nature of childhood leukemia and lymphoma.

J H Kersey, K J Gajl-Peczalska, P F Coccia, M E Nesbit.   

Abstract

One hundred consecutive newly diagnosed cases of leukemia and lymphoma in children from 0 to 16 years of age presenting at the University of Minnesota from 1973 to 1977 were studied. Clinical features were correlated with phenotypic features of blast cells, including surface markers and cytomorphology. Four groups with distinct clinical and pathologic features emerged from the study: a) The acute leukemias of the "null" or "undifferentiated" group were those in which the malignant cells carried distinctive null leukemia surface antigen and lacked features of either T cells (E-rosette positivity) or B cells (surface immunoglobulin positivity). These cases occurred most frequently in the series (56% of total cases), peaked in incidence at 6 years, were associated with extensive bone marrow involvement, lacked distinguishing cytomorphologic features, and had the best response to therapy of all groups. b) The acute myelogenous leukemias, including those with myeloid, monocytoid, or erythroid features or a combination of the above, had extensive bone marrow involvement and the characteristic morphology. This group was seen with intermediate frequency and showed an intermediate response to therapy. c) Leukemia-lymphomas of the T-cell group were frequently associated with mediastinal masses and other masses, a cytomorphology which was different from the B-cell group but similar to the null group, and high white cell counts. These cases occurred with intermediate frequency (14%) and had a worse prognosis than the null group. d) Leukemia-lymphomas of the B-cell group had monoclonal surface immunoglobulin with mu-heavy and either kappa or lambda light chain. These patients were least frequent in the series, frequently presented with abdominal masses, and had a characteristic Burkitt cell morphology. Prognosis was the worst of all patients in our series. These data suggest that the major phenotypic groups of childhood leukemia and lymphoma have differing prognoses and should receive differing forms of therapy. Clinical and pathologic features of each group are sufficiently distinctive to suggest that they may have different causes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 304675      PMCID: PMC2018141     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  12 in total

1.  T and B lymphocytes in humans. A review.

Authors:  J H Kersey; J Gajl-Peczalska
Journal:  Am J Pathol       Date:  1975-11       Impact factor: 4.307

2.  Lymphocytes bearing receptors for both sheep erythrocytes and complement in patients with neoplastic and non-neoplastic diseases.

Authors:  K J Gajl-Peczalska; S Chartrand; C D Bloomfield; J Corte; P F Coccia; M E Nesbit; J H Kersey
Journal:  Clin Immunol Immunopathol       Date:  1977-09

3.  Prognostic significance of surface marker analysis in childhood non-Hodgkin's lymphoproliferative malifnancies.

Authors:  P F Coccia; J H Kersey; K J Gajil-Peczalska; W Krivit; M E Nesbit
Journal:  Am J Hematol       Date:  1976       Impact factor: 10.047

4.  Acute leukemia with Burkitt's tumor cells: A study of six cases with special reference to lymphocyte surface markers.

Authors:  G Flandrin; J C Brouet; M T Daniel; J L Preud'homme
Journal:  Blood       Date:  1975-02       Impact factor: 22.113

5.  Surface markers and prognostic factors in acute lymphoblastic leukemia.

Authors:  I Tsukimoto; K Y Wong; B C Lampkin
Journal:  N Engl J Med       Date:  1976-01-29       Impact factor: 91.245

6.  Chronic lymphoproliferative disorder with unusual clinical, morphologic, ultrastructural and membrane surface marker characteristics.

Authors:  R W McKenna; J Parkin; J H Kersey; K J Gajl-Peczalska; L Peterson; R D Brunning
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

7.  Clinical importance of lymphoblasts with T markers in childhood acute leukemia.

Authors:  L Sen; L Borella
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

8.  Non-endemic Burkitts's lymphoma. A B-cell tumor related to germinal centers.

Authors:  R B Mann; E S Jaffe; R C Braylan; K Nanba; M M Frank; J L Ziegler; C W Berard
Journal:  N Engl J Med       Date:  1976-09-23       Impact factor: 91.245

9.  T and B lymphocyte antigen-positive null cell leukemias.

Authors:  J Kaplan; Y Ravindranath; W D Peterson
Journal:  Blood       Date:  1977-03       Impact factor: 22.113

10.  Human B-lymphocyte antigens expressed by lymphocytic and myelocytic leukemia cells. I. Detection by rabbit antisera.

Authors:  R Billing; B Rafizadeh; I Drew; G Hartman; R Gale; P Terasaki
Journal:  J Exp Med       Date:  1976-07-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Malignant lymphomas--a conceptual understanding of morphologic diversity. A review.

Authors:  R B Mann; E S Jaffe; C W Berard
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

2.  Radiological bone changes in T-cell and "common" ALL of childhood.

Authors:  E M Sweet; M L Willoughby
Journal:  Br Med J       Date:  1980-02-09

3.  Dyspnea in a pregnant young woman.

Authors:  B W Case; S Benaroya
Journal:  Can Med Assoc J       Date:  1980-04-19       Impact factor: 8.262

4.  Vertebral involvement in childhood acute lymphoblastic leukemia.

Authors:  K S Nadkarni; S H Advani; K A Dinshaw; R Gopal; C N Nair; I M Chandwani; P M Kutty
Journal:  Indian J Pediatr       Date:  1984 Jan-Feb       Impact factor: 1.967

5.  Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.

Authors:  Y Haruta; B K Seon
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 6.  Childhood acute lymphoblastic leukaemia: a review.

Authors:  M L Willoughby
Journal:  J R Soc Med       Date:  1982-06       Impact factor: 18.000

Review 7.  Malignant lymphomas as tumours of the immune system.

Authors:  C W Berard; J Cossman; E S Jaffe
Journal:  Br J Cancer       Date:  1980-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.